who in large measure has brought pressure to bear on the FDA to examine the pediatric data. Dr Healy shed light on FDA’s asymmetric standards for evaluating efficacy and safety, and presented newly uncovered documents.
Dr. Healy’s power point presentation
Accompanying text for Dr. Healy’s power point slides
Appendix – Brecher Document (140 K pdf)
AHRP’s September 14, 2004 press statement re the FDA & concealment of suicide-related risks of antidepressants
AHRP’s testimony submitted to the FDA Psychopharmacological Drugs Advisory Committee and Pediatric Subcommittee Drugs Advisory Committee at the September 13-14, 2004 Meeting RE: Suicidality Associated with Antidepressant Drug Treatment
AHRP’s press release announcing AHRP’s September 14 press briefing
David Healy’s response (502K pdf file) to a slanderous personal attack by Pfizer, posted by the FDA on FDA’s website, August 20